References
- Haller JA, Bandello F, Belfort R Jr et al.; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118(12), 2453–2460 (2011).
- The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am. J. Ophthalmol. 98(3), 271–282 (1984).
- The Central Vein Occlusion Study Group M. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 102(10), 1425–1433 (1995).
- Ip MS, Scott IU, VanVeldhuisen PC et al.; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch. Ophthalmol. 127(9), 1101–1114 (2009).
- Brown DM, Kaiser PK, Michels M et al.; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1432–1444 (2006).
- Rosenfeld PJ, Brown DM, Heier JS et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1419–1431 (2006).
- Campochiaro PA, Brown DM, Awh CC et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a Phase III study. Ophthalmology 118(10), 2041–2049 (2011).
- Figueroa MS, Contreras I, Noval S, Arruabarrena C. Results of bevacizumab as the primary treatment for retinal vein occlusions. Br. J. Ophthalmol. 94(8), 1052–1056 (2010).
- Heier JS, Brown DM, Chong V et al.; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119(12), 2537–2548 (2012).
- Brown DM, Heier JS, Clark WL et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the Phase 3 COPERNICUS study. Am. J. Ophthalmol. 155(3), 429.e7–437.e7 (2013).
- Holz FG, Roider J, Ogura Y et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the Phase III GALILEO study. Br. J. Ophthalmol. 97(3), 278–284 (2013).
- Do DV, Nguyen QD, Boyer D et al.; DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 119(8), 1658–1665 (2012).
- Campochiaro PA, Channa R, Berger BB et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a Phase I/II study. Am. J. Ophthalmol. 155(4), 697–704, 704.e1 (2013).